Cadrenal Therapeutics, Inc.(CVKD)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

CVKD Cadrenal Therapeutics, Inc.

盘前交易 09-18 05:11:52 EDT

1.12

+0.04

+3.70%

盘前1.12

+0.000.00%

04:00 EDT

最高1.14	最低1.08	成交量4.49万
今开1.10	昨收1.08	日振幅5.56%
总市值399.57万	流通市值360.98万	总股本356.76万
成交额4.96万	换手率1.39%	流通股本322.30万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"CVKD","market":"US","secType":"STK","nameCN":"Cadrenal Therapeutics, Inc.","latestPrice":1.12,"timestamp":1789675200000,"preClose":1.08,"halted":0,"volume":44902,"hourTrading":{"tag":"盘前","latestPrice":1.12,"preClose":1.12,"latestTime":"04:00 EDT","volume":100,"amount":112.00000000000001,"timestamp":1789718404851,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.03703703703703707,"floatShares":3223023,"shares":3567600,"eps":-4.866724,"marketStatus":"盘前交易","change":0.04,"latestTime":"09-18 05:11:52 EDT","open":1.1,"high":1.14,"low":1.08,"amount":49588.57889699999,"amplitude":0.055556,"askPrice":1.23,"askSize":100,"bidPrice":0.9145,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-4.866724,"tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1789738200000},"marketStatusCode":1,"adr":0,"listingDate":1674190800000,"exchange":"NASDAQ","adjPreClose":1.12,"preHourTrading":{"tag":"盘前","latestPrice":1.12,"preClose":1.12,"latestTime":"04:00 EDT","volume":100,"amount":112.00000000000001,"timestamp":1789718404851,"change":0,"changeRate":0,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":1.09,"preClose":1.12,"latestTime":"19:30 EDT","volume":2148,"amount":2412.72,"timestamp":1789687802362,"change":-0.03,"changeRate":-0.026786,"amplitude":0.035714},"volumeRatio":0.4383787931316836},"requestUrl":"/m/hq/s/CVKD/tweets","defaultTab":"tweets","newsList":[{"id":"1158643487","title":"Cadrenal Therapeutics：FDA就CAD-1005三期研究优化主要终点定义达成一致","url":"https://stock-news.laohu8.com/highlight/detail?id=1158643487","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1158643487?lang=zh_cn&edition=full","pubTime":"2026-08-31 20:02","pubTimestamp":1788177763,"startTime":"0","endTime":"0","summary":"Cadrenal Therapeutics（CVKD）宣布，美国食品药品监督管理局（FDA）已就CAD-1005三期临床研究优化后的主要终点定义达成一致意见。此次调整旨在更精准地评估药物疗效，为后续审评路径铺平道路。这一进展标志着该候选药物在关键性试验设计上迈出重要一步，有望加速其临床开发进程。公司表示，新定义将更好地反映治疗目标，同时兼顾统计学严谨性与临床实际意义。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","CVKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1157367322","title":"Cadrenal Therapeutics启动三期临床试验，采用ISTH标准评估出血事件作为主要安全终点","url":"https://stock-news.laohu8.com/highlight/detail?id=1157367322","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1157367322?lang=zh_cn&edition=full","pubTime":"2026-08-31 20:02","pubTimestamp":1788177751,"startTime":"0","endTime":"0","summary":"Cadrenal Therapeutics公司近日宣布，其即将开展的三期临床试验将采用国际血栓与止血学会（ISTH）制定的标准，把出血事件作为主要安全评价指标。这一决策标志着该公司在研药物研发进程中的重要里程碑。值得关注的是，该临床试验的设计紧扣临床实际需求，力求通过严谨的科学评估，全面衡量候选药物的安全性特征。通过将出血风险列为核心安全终点，研究团队期望能更精准地描绘出药物的风险-获益轮廓。此举不仅体现了监管层面对于出血风险的重视，也反映出企业在临床开发策略上日趋成熟与审慎。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","CVKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1101522013","title":"Cadrenal Therapeutics：FDA同意CAD-1005三期试验采用安慰剂对照联合标准抗凝治疗","url":"https://stock-news.laohu8.com/highlight/detail?id=1101522013","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1101522013?lang=zh_cn&edition=full","pubTime":"2026-08-31 20:01","pubTimestamp":1788177713,"startTime":"0","endTime":"0","summary":"Cadrenal Therapeutics宣布，美国食品药品监督管理局（FDA）已同意其CAD-1005三期临床试验采用安慰剂对照联合标准抗凝治疗的方案。这一监管决定标志着该药物研发进程中的关键节点，为后续临床评估铺平了道路。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","CVKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1166554205","title":"Cadrenal Therapeutics宣布：FDA Type D会议就CAD-1005治疗肝素诱导性血小板减少症的III期注册研究给出积极结果","url":"https://stock-news.laohu8.com/highlight/detail?id=1166554205","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1166554205?lang=zh_cn&edition=full","pubTime":"2026-08-31 20:01","pubTimestamp":1788177675,"startTime":"0","endTime":"0","summary":"Cadrenal Therapeutics对外宣布，其与FDA举行的Type D会议取得了积极成果。此次会议聚焦于CAD-1005在肝素诱导性血小板减少症治疗领域的III期注册研究方案。该公司对这一监管层面的积极信号表示欢迎，并认为这将有助于加速CAD-1005的临床开发进程。针对肝素诱导性血小板减少症这一严重且具有挑战性的适应症，该候选药物的潜在价值正逐步获得监管机构的认可。会议的积极结果，也预示着Cadrenal Therapeutics在满足未竟医疗需求方面，又向前迈出了坚实的一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","CVKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1152151319","title":"Cadrenal Therapeutics公布2026年第二季度财报，并更新心脏急救护理业务与战略合作进程","url":"https://stock-news.laohu8.com/highlight/detail?id=1152151319","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1152151319?lang=zh_cn&edition=full","pubTime":"2026-08-14 04:19","pubTimestamp":1786652373,"startTime":"0","endTime":"0","summary":"Cadrenal Therapeutics于今日发布了2026年第二季度的财务业绩。与此同时，该公司还就其心脏急性危重症护理业务线，以及正在推进的战略合作伙伴遴选流程，提供了最新情况说明。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","CVKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1150374108","title":"竞争对手三期临床试验终止，Cadrenal Therapeutics 巩固CAD-1005在心脏急性重症监护领域的多适应症战略","url":"https://stock-news.laohu8.com/highlight/detail?id=1150374108","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1150374108?lang=zh_cn&edition=full","pubTime":"2026-08-03 20:35","pubTimestamp":1785760540,"startTime":"0","endTime":"0","summary":"在竞争对手宣布终止其三期临床试验之后，Cadrenal Therapeutics 正着力强化其主打药物CAD-1005在心脏急性重症监护领域的多适应症布局。这一战略调整，彰显了该公司对市场动态的敏锐把握，以及其在心血管急症治疗赛道上的坚定决心。通过聚焦于更广泛的适应症组合，Cadrenal 旨在为临床医生提供更灵活、更具针对性的治疗选项，从而在竞争格局重塑之际，抢占先机。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CVKD","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1180034060","title":"Cadrenal Therapeutics宣布根据纳斯达克规则进行最高880万美元的市价私募配售","url":"https://stock-news.laohu8.com/highlight/detail?id=1180034060","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1180034060?lang=zh_cn&edition=full","pubTime":"2026-07-01 08:02","pubTimestamp":1782864135,"startTime":"0","endTime":"0","summary":"Cadrenal Therapeutics宣布，将依据纳斯达克市场规则，进行一项最高融资额达880万美元的私募配售，本次配售定价将采用市价基准。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CVKD","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1133455255","title":"Cadrenal 治疗公司拟就Tecarfarin用于川崎病向FDA申请罕见儿科疾病认定","url":"https://stock-news.laohu8.com/highlight/detail?id=1133455255","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1133455255?lang=zh_cn&edition=full","pubTime":"2026-06-18 21:01","pubTimestamp":1781787690,"startTime":"0","endTime":"0","summary":"Cadrenal 治疗公司宣布，计划为其候选药物Tecarfarin在川崎病治疗中的应用，向美国食品药品监督管理局提交罕见儿科疾病认定申请。此举旨在加速该药物针对这一儿童血管炎症的研发与审批进程。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CVKD","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1175510557","title":"Cadrenal Therapeutics推进CAD-1005多适应症战略；启动2a期急性肾损伤临床计划，旨在加速Bio 2026大会上的医药合作","url":"https://stock-news.laohu8.com/highlight/detail?id=1175510557","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1175510557?lang=zh_cn&edition=full","pubTime":"2026-06-15 20:32","pubTimestamp":1781526775,"startTime":"0","endTime":"0","summary":"Cadrenal Therapeutics正在积极推进其候选药物CAD-1005的多适应症开发战略。公司宣布启动一项针对心脏手术相关急性肾损伤（CSA-AKI）的2a期临床研究计划。此举旨在加速该药物的临床开发进程，并为即将到来的Bio 2026国际生物技术大会上的潜在医药合作伙伴关系奠定基础。通过展示CAD-1005在急性肾损伤这一未满足医疗需求领域的临床进展，公司期望能吸引合作伙伴，共同推进该药物在多个治疗领域的开发。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CVKD","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1193713152","title":"Cadrenal Therapeutics任命Quang X. Pham为临时首席财务官及临时首席会计官","url":"https://stock-news.laohu8.com/highlight/detail?id=1193713152","media":"美股速递","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1193713152?lang=zh_cn&edition=full","pubTime":"2026-06-04 04:27","pubTimestamp":1780518468,"startTime":"0","endTime":"0","summary":"根据美国证券交易委员会（SEC）提交的最新文件，Cadrenal Therapeutics, Inc. 已正式任命Quang X. Pham担任公司临时首席财务官及临时首席会计官。\n这一人事任命标志着该公司在关键财务领导职位上进行了重要调整。临时首席财务官将负责监督公司的整体财务战略、规划及报告工作，而临时首席会计官则将专注于会计操作、内部控制及财务合规性事务。\n公司此举旨在确保其财务职能在过渡期间的连续性与稳定性。新任命的两位临时职位预计将为Cadrenal Therapeutics的财务管理和会计实践带来专业的领导力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","CVKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1194469680","title":"Cadrenal Therapeutics公布2026年第一季度财报 并在完成FDA二期结束会议后更新CAD-1005三期研发进展","url":"https://stock-news.laohu8.com/highlight/detail?id=1194469680","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1194469680?lang=zh_cn&edition=full","pubTime":"2026-05-07 20:30","pubTimestamp":1778157035,"startTime":"0","endTime":"0","summary":"Cadrenal Therapeutics, Inc.披露了2026年第一季度的财务业绩，同时就核心药物CAD-1005的三期临床试验规划提供了最新动态。此次进展基于公司与美国食品药品监督管理局（FDA）成功举行的二期临床试验结束会议后所制定的后续开发路径。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CVKD","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1149542500","title":"Cadrenal Therapeutics宣布完成FDA二期临床试验结束会议 确立CAD-1005治疗肝素诱导血小板减少症的关键三期注册路径","url":"https://stock-news.laohu8.com/highlight/detail?id=1149542500","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1149542500?lang=zh_cn&edition=full","pubTime":"2026-04-30 20:31","pubTimestamp":1777552310,"startTime":"0","endTime":"0","summary":"Cadrenal Therapeutics近日宣布已顺利完成与美国食品药品监督管理局（FDA）针对CAD-1005药物治疗肝素诱导血小板减少症（HIT）的二期临床试验结束会议。此次会议明确了该药物进入关键性三期注册临床试验的路径规划，标志着CAD-1005在HIT治疗领域的研发进程迈入新阶段。\n此次会议成果为后续临床试验方案设计提供了明确指引。公司计划基于会议共识加快推进三期临床试验筹备工作，力争早日为HIT患者提供新的治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CVKD","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1120840144","title":"Cadrenal Therapeutics公司提交招股说明书 股东拟转售最高120万股普通股","url":"https://stock-news.laohu8.com/highlight/detail?id=1120840144","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1120840144?lang=zh_cn&edition=full","pubTime":"2026-04-21 18:10","pubTimestamp":1776766215,"startTime":"0","endTime":"0","summary":"根据美国证券交易委员会最新披露文件显示，生物制药公司Cadrenal Therapeutics已正式提交招股说明书，公司现有股东计划通过二级市场转售最多120万股普通股。\n此次转售计划涉及由部分现有股东持有的公司普通股，总规模上限为120万股。招股说明书的提交标志着相关股东已获得通过公开市场减持股份的资格，为后续股份流通铺平道路。\n作为专注于心血管疾病创新疗法研发的临床阶段生物技术企业，Cadrenal Therapeutics此次股东股份转售安排引发市场关注。文件显示，此次股份转售将完全由售股股东自主进行，公司不会从此次售股中获得任何收益。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CVKD","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1175758588","title":"Cadrenal Therapeutics公布2025年第四季度财报 披露CAD-1005项目二期临床结束后获FDA积极反馈","url":"https://stock-news.laohu8.com/highlight/detail?id=1175758588","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1175758588?lang=zh_cn&edition=full","pubTime":"2026-03-31 20:45","pubTimestamp":1774961149,"startTime":"0","endTime":"0","summary":"Cadrenal Therapeutics公司近日发布了2025年第四季度财务报告，同时就CAD-1005研发项目的最新进展进行了说明。该项目在完成二期临床试验后，已与美国食品药品监督管理局（FDA）举行阶段性会议，并获得了积极反馈。\n此次财报披露了公司在第四季度的财务表现，而企业更新重点聚焦于CAD-1005项目的后续发展。该药物项目在达成二期临床终点后，与监管机构的沟通取得了关键进展，为后续研发路径奠定了重要基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","CVKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1107150282","title":"Cadrenal Therapeutics 强调研究支持12-LOX抑制在减少肥胖和2型糖尿病炎症中的作用","url":"https://stock-news.laohu8.com/highlight/detail?id=1107150282","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1107150282?lang=zh_cn&edition=full","pubTime":"2026-03-12 20:02","pubTimestamp":1773316933,"startTime":"0","endTime":"0","summary":"Cadrenal Therapeutics 重点介绍了一项研究，该研究支持通过抑制12-脂氧合酶（12-LOX）来减轻肥胖及2型糖尿病相关的炎症反应。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","CVKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2518240132","title":"Cadrenal Therapeutics, Inc.盘中异动 早盘股价大跌5.04%报16.00美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2518240132","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2518240132?lang=zh_cn&edition=full","pubTime":"2025-03-10 21:35","pubTimestamp":1741613715,"startTime":"0","endTime":"0","summary":"北京时间2025年03月10日21时35分，Cadrenal Therapeutics, Inc.股票出现异动，股价急速跳水5.04%。Cadrenal Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.07%。Cadrenal Therapeutics, Inc.公司简介：Cadrenal Therapeutics Inc专注于开发一种具有孤儿药指征的新疗法——替卡法林，用于预防终末期肾病(透析中)和房颤或AFib患者的心脏源性系统性血栓栓塞(血凝块)。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310213515a26a2622&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310213515a26a2622&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","BK4007","CVKD","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516658719","title":"Cadrenal Therapeutics, Inc.盘中异动 快速下跌5.14%","url":"https://stock-news.laohu8.com/highlight/detail?id=2516658719","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2516658719?lang=zh_cn&edition=full","pubTime":"2025-03-03 23:54","pubTimestamp":1741017248,"startTime":"0","endTime":"0","summary":"北京时间2025年03月03日23时54分，Cadrenal Therapeutics, Inc.股票出现异动，股价快速下跌5.14%。Cadrenal Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.39%。Cadrenal Therapeutics, Inc.公司简介：Cadrenal Therapeutics Inc专注于开发一种具有孤儿药指征的新疗法——替卡法林，用于预防终末期肾病(透析中)和房颤或AFib患者的心脏源性系统性血栓栓塞(血凝块)。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250303235408989a24c5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250303235408989a24c5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","BK4007","CVKD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514320236","title":"Cadrenal Therapeutics, Inc.盘中异动 早盘股价大涨5.12%报19.35美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514320236","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2514320236?lang=zh_cn&edition=full","pubTime":"2025-02-28 22:31","pubTimestamp":1740753102,"startTime":"0","endTime":"0","summary":"北京时间2025年02月28日22时31分，Cadrenal Therapeutics, Inc.股票出现波动，股价快速上涨5.12%。截至发稿，该股报19.35美元/股，成交量1510股，换手率0.08%，振幅0.00%。Cadrenal Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.02%。Cadrenal Therapeutics, Inc.公司简介：Cadrenal Therapeutics Inc专注于开发一种具有孤儿药指征的新疗法——替卡法林，用于预防终末期肾病(透析中)和房颤或AFib患者的心脏源性系统性血栓栓塞(血凝块)。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250228223142989679a6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250228223142989679a6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","CVKD","BK4139","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514892503","title":"Cadrenal Therapeutics, Inc.盘中异动 早盘快速上涨5.49%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514892503","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2514892503?lang=zh_cn&edition=full","pubTime":"2025-02-27 23:18","pubTimestamp":1740669507,"startTime":"0","endTime":"0","summary":"北京时间2025年02月27日23时18分，Cadrenal Therapeutics, Inc.股票出现波动，股价急速上涨5.49%。Cadrenal Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.88%。Cadrenal Therapeutics, Inc.公司简介：Cadrenal Therapeutics Inc专注于开发一种具有孤儿药指征的新疗法——替卡法林，用于预防终末期肾病(透析中)和房颤或AFib患者的心脏源性系统性血栓栓塞(血凝块)。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025022723182798951a89&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025022723182798951a89&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","LENZ","CVKD","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514263854","title":"Cadrenal Therapeutics, Inc.盘中异动 早盘股价大涨5.16%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514263854","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2514263854?lang=zh_cn&edition=full","pubTime":"2025-02-26 23:34","pubTimestamp":1740584097,"startTime":"0","endTime":"0","summary":"北京时间2025年02月26日23时34分，Cadrenal Therapeutics, Inc.股票出现波动，股价急速拉升5.16%。Cadrenal Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.08%。Cadrenal Therapeutics, Inc.公司简介：Cadrenal Therapeutics Inc专注于开发一种具有孤儿药指征的新疗法——替卡法林，用于预防终末期肾病(透析中)和房颤或AFib患者的心脏源性系统性血栓栓塞(血凝块)。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250226233457a25505c1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250226233457a25505c1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","CVKD","BK4007","LENZ"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.cadrenal.com","stockEarnings":[{"period":"1week","weight":-0.0508},{"period":"1month","weight":-0.345},{"period":"3month","weight":-0.68},{"period":"6month","weight":-0.8282},{"period":"1year","weight":-0.9114},{"period":"ytd","weight":-0.8348}],"compareEarnings":[{"period":"1week","weight":0.0063},{"period":"1month","weight":-0.0063},{"period":"3month","weight":0.0212},{"period":"6month","weight":0.1758},{"period":"1year","weight":0.1569},{"period":"ytd","weight":0.1183}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Cadrenal Therapeutics, Inc.于2022年1月25日注册为特拉华州公司。该公司正在开发公司候选药物替卡法林，用于抗凝治疗方面未满足的需求。替卡法林是一种晚期新型口服和可逆抗凝血剂（血液稀释剂），用于预防心脏病发作、中风，以及需要慢性抗凝的罕见心血管疾病患者因血栓而死亡。","yearOnYearQuotes":[{"month":1,"riseRate":1,"avgChangeRate":0.616418},{"month":2,"riseRate":0.25,"avgChangeRate":-0.178681},{"month":3,"riseRate":0,"avgChangeRate":-0.223506},{"month":4,"riseRate":0.25,"avgChangeRate":-0.023558},{"month":5,"riseRate":0.5,"avgChangeRate":-0.07843},{"month":6,"riseRate":0.25,"avgChangeRate":-0.090504},{"month":7,"riseRate":0,"avgChangeRate":-0.261736},{"month":8,"riseRate":0.5,"avgChangeRate":0.04744},{"month":9,"riseRate":0.5,"avgChangeRate":0.095723},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.040335},{"month":11,"riseRate":0.333333,"avgChangeRate":-0.124766},{"month":12,"riseRate":0.333333,"avgChangeRate":0.094875}],"exchange":"NASDAQ","name":"Cadrenal Therapeutics, Inc.","nameEN":"Cadrenal Therapeutics, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.0","shortVersion":"4.50.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Cadrenal Therapeutics, Inc.(CVKD)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Cadrenal Therapeutics, Inc.(CVKD)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Cadrenal Therapeutics, Inc.,CVKD,Cadrenal Therapeutics, Inc.股票,Cadrenal Therapeutics, Inc.股票老虎,Cadrenal Therapeutics, Inc.股票老虎国际,Cadrenal Therapeutics, Inc.行情,Cadrenal Therapeutics, Inc.股票行情,Cadrenal Therapeutics, Inc.股价,Cadrenal Therapeutics, Inc.股市,Cadrenal Therapeutics, Inc.股票价格,Cadrenal Therapeutics, Inc.股票交易,Cadrenal Therapeutics, Inc.股票购买,Cadrenal Therapeutics, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Cadrenal Therapeutics, Inc.(CVKD)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Cadrenal Therapeutics, Inc.(CVKD)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}